Key Considerations for the Management of RSV in Adult Patients : Episode 8

Opinion

Video

July 15, 2024

Financial and Clinical Benefits of RSV Immunization

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Wanda Filer, MD, MBA

Following the recent approval of RSV vaccines, the panel discusses the financial and clinical benefits, highlighting the fiscal impact seen in hospitals and ICUs.

EP: 1.Overview of RSV Patient Populations

EP: 2.Complications Associated with RSV Infections

EP: 3.The Economic Burden and Main Drivers of Healthcare Resource Utilization in RSV

EP: 4.RSV: Risk Factors and How It’s Spread

EP: 5.Diagnostic Practices for RSV

EP: 6.Increasing Awareness of RSV Vaccines in At-Risk Patients

EP: 7.Shared Decision-Making Practices in RSV

EP: 8.Financial and Clinical Benefits of RSV Immunization

EP: 9.The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59

EP: 10.Addressing Vaccine Fatigue

EP: 11.Identifying Patients Eligible for RSV Vaccine

EP: 12.Current and Potential Obstacles Related to Administering RSV Vaccines

EP: 13.Improving Insurance Coverage for RSV Vaccines

EP: 14.Improving RSV Vaccination Rates and Addressing Misinformation

EP: 15.Key Takeaways on RSV Vaccination

Video content above is prompted by the following questions:

With RSV vaccines newly approved, what are the financial and clinical goals associated with immunizing against RSV?
Have payers activated early coverage for the adult RSV vaccines since they entered to reduce costs?
- How have RSV vaccines altered the fiscal impact associated with managing RSV infections in hospitals or ICUs?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

4 experts in this video

4 experts in this video

Related Content

Clinician holding RSV vaccine | Image Credit: kitsawet - stock.adobe.com

May 14th 2025

Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use

Brooke McCormick

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.

RSV, COVID, Flu vaccines. | Image credit: angellodeco - stock.adobe.com

February 19th 2025

Nirsevimab, RSVpreF Saw High Uptake With No Preterm Risk for RSVpreF

High vaccine uptake shows promise for the prevention of respiratory syncytial virus (RSV) in infants.

Nursing home care | Image credit: Kzenon - stock.adobe.com

November 24th 2024

Low RSV Vaccination Rates in Nursing Homes Highlight Urgent Need for Uptake

Significant gaps in vaccination coverage among nursing home residents leaves vulnerable populations at risk for severe complications, report finds.

Air purifier | Image credit: Prathankarnpap - stock.adobe.com

November 22nd 2024

In-Room Air Purifiers Could Impact RSV Incidence Among Older Adults

Kennedy Ferruggia

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

RSV risk survey | Image credit: Richelle - stock.adobe.com

November 20th 2024

Community Pharmacies Hold Key Role in Protecting Older Adults From RSV

New research reveals gaps in respiratory syncytial virus (RSV) knowledge among older adults and emphasizes the impact community pharmacies can have at improving education and vaccine uptake.

Blood sample tube for RSV test. | Image credit: JUN LI - stock.adobe.com

November 15th 2024

RSV Vaccine Proven Effective in Reducing RSV-Related Hospitalizations

Kennedy Ferruggia

Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.

Related Content

Clinician holding RSV vaccine | Image Credit: kitsawet - stock.adobe.com

May 14th 2025

Infant RSV Hospitalization Rates Drop in First Season With Widespread Preventive Product Use

Brooke McCormick

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the importance of timely vaccination and nirsevimab administration.

RSV, COVID, Flu vaccines. | Image credit: angellodeco - stock.adobe.com

February 19th 2025

Nirsevimab, RSVpreF Saw High Uptake With No Preterm Risk for RSVpreF

High vaccine uptake shows promise for the prevention of respiratory syncytial virus (RSV) in infants.

Nursing home care | Image credit: Kzenon - stock.adobe.com

November 24th 2024

Low RSV Vaccination Rates in Nursing Homes Highlight Urgent Need for Uptake

Significant gaps in vaccination coverage among nursing home residents leaves vulnerable populations at risk for severe complications, report finds.

Air purifier | Image credit: Prathankarnpap - stock.adobe.com

November 22nd 2024

In-Room Air Purifiers Could Impact RSV Incidence Among Older Adults

Kennedy Ferruggia

Use of in-room air purifiers with HEPA-14 filters did not result in a significant reduction of acute respiratory infections.

RSV risk survey | Image credit: Richelle - stock.adobe.com

November 20th 2024

Community Pharmacies Hold Key Role in Protecting Older Adults From RSV

New research reveals gaps in respiratory syncytial virus (RSV) knowledge among older adults and emphasizes the impact community pharmacies can have at improving education and vaccine uptake.

Blood sample tube for RSV test. | Image credit: JUN LI - stock.adobe.com

November 15th 2024

RSV Vaccine Proven Effective in Reducing RSV-Related Hospitalizations

Kennedy Ferruggia

Respiratory syncytial virus (RSV) vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults, study finds.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions